cua cà mau cua tươi sống cua cà mau bao nhiêu 1kg giá cua hôm nay giá cua cà mau hôm nay cua thịt cà mau cua biển cua biển cà mau cách luộc cua cà mau cua gạch cua gạch cà mau vựa cua cà mau lẩu cua cà mau giá cua thịt cà mau hôm nay giá cua gạch cà mau giá cua gạch cách hấp cua cà mau cua cốm cà mau cua hấp mua cua cà mau cua ca mau ban cua ca mau cua cà mau giá rẻ cua biển tươi cuaganic cua cua thịt cà mau cua gạch cà mau cua cà mau gần đây hải sản cà mau cua gạch son cua đầy gạch giá rẻ các loại cua ở việt nam các loại cua biển ở việt nam cua ngon cua giá rẻ cua gia re crab farming crab farming cua cà mau cua cà mau cua tươi sống cua tươi sống cua cà mau bao nhiêu 1kg giá cua hôm nay giá cua cà mau hôm nay cua thịt cà mau cua biển cua biển cà mau cách luộc cua cà mau cua gạch cua gạch cà mau vựa cua cà mau lẩu cua cà mau giá cua thịt cà mau hôm nay giá cua gạch cà mau giá cua gạch cách hấp cua cà mau cua cốm cà mau cua hấp mua cua cà mau cua ca mau ban cua ca mau cua cà mau giá rẻ cua biển tươi cuaganic cua cua thịt cà mau cua gạch cà mau cua cà mau gần đây hải sản cà mau cua gạch son cua đầy gạch giá rẻ các loại cua ở việt nam các loại cua biển ở việt nam cua ngon cua giá rẻ cua gia re crab farming crab farming cua cà mau
Skip to main content

FDA says it’s a terrible idea to use hydroxychloroquine to treat coronavirus at home

The U.S. Food and Drug Administration (FDA) issued a warning Friday about the “potentially life-threatening” side effects of using hydroxychloroquine and chloroquine to treat the coronavirus outside of a hospital setting or without doctor supervision. 

hydroxychloroquine
Hydroxychloroquine NurPhoto / Getty Images

The FDA warned there is a possibility for “serious heart-related adverse events and death” in patients who take the drugs to recover from the coronavirus, officially known as COVID-19.

Recommended Videos

“While clinical trials are ongoing to determine the safety and effectiveness of these drugs for COVID-19, there are known side effects of these medications that should be considered,” said FDA Commissioner Stephen M. Hahn. “We encourage health care professionals making individual patient decisions closely screen and monitor those patients to help mitigate these risks.”

The announcement comes after the drug has been widely promoted through social media and by President Donald Trump, who said the drug had the potential to work as a treatment for the disease that has infected nearly 900,000 Americans in the past few months. 

The agency’s move Friday to warn Americans against taking the drugs without medical supervision comes after weeks of hype about hydroxychloroquine on social media, which led some platforms like Twitter to take sweeping action to remove the misinformation. The drug was even pushed by President Donald Trump, who said the drug had the potential to work as a treatment for the disease that has infected nearly 900,000 Americans in the past few months.

Other government agencies have followed suit in backing off of using hydroxychloroquine to treat COVID-19. The Centers for Disease Control and Prevention (CDC) updated its information page about the drugs and removed its recommendation for dosage, citing a lack of scientific evidence. 

Earlier this month, a Mayo Clinic cardiologist said there is potentially fatal danger in promoting the use of the drug, aiming criticism directly at Trump, who has mentioned them frequently in his daily coronavirus press briefings. 

In March, the FDA made a controversial decision when it authorized chloroquine and hydroxychloroquine to be added to the Strategic National Stockpile. The drugs are better known to treat malaria, and have been found to greatly inhibit a person’s immune system, making them useful to treat autoimmune diseases. 

The FDA said it will continue to monitor clinical trials of the drugs and will allow them to be used in hospital settings. 

Meira Gebel
Former Digital Trends Contributor
Meira Gebel is a freelance reporter based in Portland. She writes about tech, social media, and internet culture for Digital…
FDA authorizes at-home coronavirus test that uses your spit
Rutgers Spectrum Coronavirus Saliva Test.

The Food and Drug Administration has authorized a second at-home test for the coronavirus -- one that can detect the virus using saliva samples.

The test is made by a Rutgers University laboratory, RUCDR Infinite Biologics, in partnership with Spectrum Solutions and Accurate Diagnostic Labs. The Rutgers test uses a saliva collection device and must be sent back to the lab for testing. You can only receive the test if it’s been ordered through a physician.

Read more
Coronavirus antibody tests aren’t created equal. Here’s what you need to know
Researcher in Lab with Blood Sample Test

The Food and Drug Administration (FDA) recently decided to tighten the regulations on coronavirus antibody tests. These tests are supposed to help people know whether they were previously infected with the virus, but the FDA admitted that many of them aren’t accurate enough to be useful.

Whether you’ve already been administered an antibody test or hope to get one in the future, here’s what you need to know about whether to trust the results.
What are antibodies?
When your body is exposed to an antigen -- or outside substance including viruses, bacteria, and certain chemicals -- it causes the immune system to attack it. As part of the response, white blood cells create a certain kind of protein called antibodies. These proteins can only bind to that specific type of antigen, and they can help the body more quickly respond to the virus or bacteria, making you less likely to get sick from the exact same strain twice.

Read more
FDA clears heart monitor for coronavirus patients using hydroxychloroquine
doctors gloved hands attaching a VitalPatch to a patient's chest

The Food and Drug Administration (FDA) today granted Emergency Use Authorization for a wearable biosensor called the VitalPatch, which can be used to monitor the heart rhythms of patients who have been treated for coronavirus with hydroxychloroquine.

The wearable patch adheres to a patient’s skin just above their heart and can be worn for seven days. It monitors for 22 different types of arrhythmia and fibrillation, as well as 11 other physiological signs, many of which coincide with symptoms of COVID-19, the disease caused by the virus, said Peter Van Haur, CEO of VitalConnect, maker of the sensor.

Read more